Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Int J Mol Sci ; 25(6)2024 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-38542085

RESUMO

Erectile dysfunction (ED) is a frequent and difficult-to-treat condition in diabetic men. Protein kinase C (PKC) is involved in diabetes-related vascular and cavernosal alterations. We aimed to evaluate the role of PKC in endothelial dysfunction and NO/cGMP impairment associated with diabetic ED in the human corpus cavernosum (CC) and penile resistance arteries (PRAs) and the potential mechanisms involved. Functional responses were determined in the CC and PRAs in patients with non-diabetic ED and diabetic ED undergoing penile prosthesis insertion. PKC activator 12,13-phorbol-dibutyrate (PDBu) impaired endothelial relaxations and cGMP generation in response to acetylcholine in the CC from non-diabetic ED. PDBu also impaired responses to a PDE5 inhibitor, sildenafil, in non-diabetic ED patients. Conversely, a PKC inhibitor, GF109203X, improved endothelial, neurogenic, and PDE5-inhibitor-induced relaxations and cGMP generation only in the CC in diabetic ED patients. Endothelial and PDE5-inhibitor-induced vasodilations of PRAs were potentiated only in diabetes. Improvements in endothelial function in diabetes were also achieved with a specific inhibitor of the PKCß2 isoform or an NADPH-oxidase inhibitor, apocynin, which prevented PDBu-induced impairment in non-diabetic patients. PKC inhibition counteracted NO/cGMP impairment and endothelial dysfunction in diabetes-related ED, potentially improving response to PDE5 inhibition.


Assuntos
Diabetes Mellitus , Disfunção Erétil , Masculino , Humanos , Disfunção Erétil/tratamento farmacológico , Disfunção Erétil/etiologia , Disfunção Erétil/metabolismo , Proteína Quinase C/metabolismo , Citrato de Sildenafila , Diabetes Mellitus/metabolismo , Pênis/irrigação sanguínea , Inibidores da Fosfodiesterase 5/farmacologia , Inibidores da Fosfodiesterase 5/uso terapêutico , Ereção Peniana
2.
Rev. int. androl. (Internet) ; 20(2): 110-115, abr.-jun. 2022. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-205408

RESUMO

Radical orchiectomy in testicular cancer patients can have a negative impact on body image and self-esteem. Reconstructive surgery with testicular prosthesis might mitigate this burden. We conducted a questionnaire-based study aiming to evaluate our patients’ satisfaction with testicular prosthesis. Overall satisfaction was rated as excellent or good in 97.7%. The main complaints were related to the prosthesis’ inappropriate texture (45.5%), size (18.1%) or position (15.9%). Among men interviewed, 59% considered that having a normal looking scrotum was either extremely important or important for their self-esteem. The majority (88.2%) stated they would make the same decision again, and nearly all patients would recommend it to other men with testicular cancer. We believe testicular implants should always be offered, leaving the final decision to the patient (AU)


La orquiectomía radical en los pacientes de cáncer de testículo puede tener un impacto negativo en su imagen corporal y autoestima. La cirugía reconstructora con prótesis testiculares podría mitigar esta carga. Realizamos un estudio basado en el uso de un cuestionario con el objetivo de evaluar la satisfacción de nuestros pacientes con las prótesis testiculares. La satisfacción general fue calificada como excelente o buena en el 97,7% de los casos. Las principales quejas guardaron relación con la textura inadecuada de las prótesis (45,5%), el tamaño (18,1%) o su posición (15,9%). Entre los varones entrevistados, el 59% consideró que tener un escroto con aspecto normal era extremadamente importante, o importante para su autoestima. La mayoría (88,2%) afirmó que volverían a tomar la misma decisión de nuevo, y casi todos los pacientes lo recomendarían a otros varones con cáncer de testículo. Consideramos que siempre deberían ofrecerse los implantes testiculares, dejando que el paciente tome siempre la decisión final. (AU)


Assuntos
Humanos , Masculino , Neoplasias Testiculares , Membros Artificiais , Orquiectomia , Neoplasias Testiculares/cirurgia , Neoplasias Testiculares/psicologia , Imagem Corporal , Autoimagem , Portugal , Inquéritos e Questionários
3.
Eur J Pharmacol ; 884: 173370, 2020 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-32712093

RESUMO

H2S signaling was proposed to participate in erectile physiology. L-cysteine (CYS)/H2S pathway stimulation causes cGMP-dependent relaxation of human corpus cavernosum (HCC) and penile arteries (HPRA). The aim was to evaluate the impact of ED on CYS/H2S pathway at functional and molecular level in human penile vascular tissues. NaHS- and CYS-induced responses were evaluated in HCC and HPRA from organ donors without ED (NoED, n = 29) and from ED patients undergoing penile prosthesis insertion (n = 45). cGMP accumulation and cystathionine ß-synthase and cystathionine γ-lyase expression were also determined. NaHS-induced relaxations were slightly but significantly impaired in HCC but not in HPRA from ED patients. In contrast, CYS-induced relaxations were markedly impaired in HCC (Emax 67.6 ± 4.9% vs 46.2 ± 4.6%, P < 0.01) and HPRA (Emax 80.8 ± 4.0% vs 48.1 ± 8.6%, P < 0.05) from men with ED. Impairment of CYS-induced responses was observed even after separating diabetic ED patients. In HPRA from ED patients, CYS- but not NaHS-induced vasodilation was significantly associated to endothelial function measured as vasodilatory capacity of acetylcholine (ACh) in these preparations (r2 = 0.481, P < 0.01). Impairment of CYS-induced relaxations was related to significant reduction in CYS-induced accumulation of cGMP in cavernosal tissue. Furthermore, the expression of H2S synthesizing enzymes was significantly reduced in HCC from ED patients with respect to NoED. This was confirmed by immunofluorescence in HCC and HPRA sections. ED involves impairment of CYS/H2S pathway in penile vascular tissues associated with decreased expression of H2S generating enzymes, CBS and CSE. These evidences support a therapeutic potential for modulation of CYS/H2S signaling in the management of ED.


Assuntos
Artérias/efeitos dos fármacos , Cisteína/farmacologia , Impotência Vasculogênica/fisiopatologia , Ereção Peniana/efeitos dos fármacos , Pênis/irrigação sanguínea , Sulfetos/farmacologia , Vasodilatação/efeitos dos fármacos , Adulto , Idoso , Artérias/metabolismo , Artérias/fisiopatologia , GMP Cíclico/metabolismo , Cistationina beta-Sintase/metabolismo , Cistationina gama-Liase/metabolismo , Cisteína/metabolismo , Humanos , Impotência Vasculogênica/metabolismo , Masculino , Pessoa de Meia-Idade , Fluxo Sanguíneo Regional , Transdução de Sinais , Sulfetos/metabolismo , Adulto Jovem
4.
Eur J Pharmacol ; 863: 172675, 2019 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-31542487

RESUMO

The aim was to evaluate and characterize H2S-induced relaxation of human corpus cavernosum (HCC) and penile resistance arteries (HPRA) from patients with erectile dysfunction (ED). HCC and HPRA were obtained from men with ED at the time of penile prosthesis insertion. H2S-mediated relaxations were evaluated by exposing these tissues to the stable analogue, NaHS, and to the precursor of H2S, L-cysteine (CYS). The effects of NaHS and CYS were also evaluated on cGMP accumulation in HCC and on acetylcholine- and sildenafil-mediated relaxations in HCC and HPRA. NaHS consistently relaxed HPRA and HCC and more potently than human prostate and bladder. NaHS-induced relaxations in HCC and HPRA were unaffected by the ATP-sensitive K+-channel blocker, glibenclamide or the NO synthase inhibitor, L-NAME, slightly reduced by the Ca2+-activated K+-channel blocker, tetraethylammonium, and markedly inhibited by the soluble guanylyl cyclase inhibitor, ODQ. NaHS caused a cGMP increase in HCC that was inhibited by ODQ. CYS produced relaxations of HCC and HPRA that were sensitive to ODQ and to inhibition of the H2S synthesizing enzymes, cystathionine γ-lyase (CSE) and cystathionine ß-synthase (CBS). CYS also increased cGMP in HCC. In contrast to NaHS, CYS-induced relaxations were prevented by endothelium removal in HPRA. Only in HPRA, treatment with CYS (30 µM) potentiated acetylcholine- and sildenafil-induced relaxations. This effect was prevented by CSE/CBS inhibition and by removing the endothelium. Exogenous and endogenous H2S relaxes HCC and HPRA from ED patients through cGMP accumulation and potentiates vasodilatory capacity of PDE5 inhibition, supporting the therapeutic potential of modulating H2S pathway.


Assuntos
Cisteína/metabolismo , Disfunção Erétil/fisiopatologia , Sulfeto de Hidrogênio/metabolismo , Relaxamento Muscular/efeitos dos fármacos , Pênis/efeitos dos fármacos , Inibidores da Fosfodiesterase 5/farmacologia , Vasodilatação/efeitos dos fármacos , Artérias/efeitos dos fármacos , Artérias/fisiopatologia , GMP Cíclico/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Pênis/irrigação sanguínea , Pênis/fisiopatologia , Citrato de Sildenafila/farmacologia
5.
J Sex Med ; 13(12): 1844-1857, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27864032

RESUMO

INTRODUCTION: Cavernous nerve injury (CNI) in rats and radical prostatectomy (RP) in men result in loss of nitrergic function and increased adrenergic-neurogenic contractions of cavernosal tissue. AIM: To evaluate the modulation of the α-adrenergic system as a strategy to relieve erectile dysfunction (ED) and functional cavernosal alterations induced by CNI. METHODS: A non-selective α-blocker (phentolamine 1 mg/kg daily), a selective α1A-blocker (silodosin [SILOD] 0.1 mg/kg daily), or vehicle was orally administered for 4 weeks after bilateral crush CNI (BCNI). Erectile and neurogenic responses of the corpus cavernosum (CC) were evaluated. The acute effects of SILOD also were evaluated in vivo (0.03 mg/kg intravenously) and ex vivo (10 nmol/L). The effects of SILOD and tadalafil (TAD) on nitrergic relaxations were determined in human CC from patients with ED with a vascular etiology or ED secondary to RP. MAIN OUTCOME MEASURES: Erectile responses in vivo in rats and neurogenic contractions and relaxations of rat and human CC. RESULTS: Long-term treatment with SILOD significantly improved erectile responses and allowed for the potentiation of erectile responses by acute treatment with TAD (0.3 mg/kg intravenously) in rats with BCNI. SILOD partly recovered nitrergic relaxations and normalized neurogenic contractions in CC from rats with BCNI. Long-term treatment with SILOD partly prevented BCNI-induced decreases in neuronal nitric oxide synthase expression. Acute administration of SILOD (0.03 mg/kg intravenously) improved erectile responses in vivo and potentiated nitrergic relaxation and decreased neurogenic contractions ex vivo in CC from rats with BCNI. In human CC from patients with ED with a vascular etiology, TAD (30 nmol/L), SILOD (10 nmol/L), or their combination increased nitrergic relaxations. Potentiation by TAD was lost in human CC from patients with ED after RP but was recovered after co-treatment with SILOD. CONCLUSION: α-Adrenergic modulation, especially selective α1A-blockade, improves erectile and cavernosal functions after BCNI. Modulation of the adrenergic system, mainly in combination strategies, could have a role in the management of ED after RP.


Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Disfunção Erétil/tratamento farmacológico , Prostatectomia/efeitos adversos , Receptores Adrenérgicos alfa 1/efeitos dos fármacos , Animais , Disfunção Erétil/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Compressão Nervosa/efeitos adversos , Óxido Nítrico Sintase Tipo I/metabolismo , Ereção Peniana/efeitos dos fármacos , Pênis/irrigação sanguínea , Traumatismos dos Nervos Periféricos/complicações , Ratos , Ratos Sprague-Dawley , Tadalafila/farmacologia , Traumatismos do Sistema Nervoso/complicações
6.
J Sex Med ; 12(3): 590-9, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25529966

RESUMO

INTRODUCTION: Radical prostatectomy (RP) frequently results in erectile dysfunction (ED). It has been hypothesized that alterations of cavernosal tissue subsequent to RP contribute to ED but functional evaluation of the impact of RP on human erectile structures is lacking. AIM: This study aims to evaluate endothelial function of human corpus cavernosum (HCC) and human penile resistance arteries (HPRA) and neurogenic responses of HCC from patients with ED secondary to RP (ED-RP). METHODS: HCC strips and HPRA were obtained from organ donors without history of ED (No-ED) and patients with ED who were segregated depending on ED etiology: ED-RP or vasculogenic (ED-VASC). Functional evaluation of HCC and HPRA was performed in organ chambers and wire myographs, respectively. Histological evaluation of cavernosal tissue consisted of trichrome staining for fibrosis quantification and TUNEL assay for determination of apoptosis. MAIN OUTCOME MEASURES: Endothelium-dependent and endothelium-independent relaxation, electrical field stimulation (EFS)-induced neurogenic contraction and relaxation, and cavernosal fibrosis and apoptosis. RESULTS: Endothelium-dependent relaxations were significantly impaired in HCC and HPRA from ED-VASC patients while these responses in ED-PR patients were not different to No-ED. Similarly, sildenafil-induced relaxations were reduced in HCC and HPRA from ED-VASC but were preserved in ED-RP. Adrenergic contractions induced by EFS in HCC were potentiated in both ED-RP and ED-VASC. EFS-induced nitrergic relaxation was significantly reduced in HCC from ED-VASC but was almost abolished in ED-RP. Fibrous tissue content and cavernosal apoptosis in HCC from ED-RP were not significantly different from No-ED. CONCLUSIONS: Endothelial function and cavernosal sensitivity to phosphodiesterase type 5 inhibitors are preserved in erectile tissue from ED-RP while a marked imbalance in neurogenic modulation of cavernosal tone favoring adrenergic contractile responses over nitrergic relaxation is manifested. Fibrotic and apoptotic processes in cavernosal tissue are not specifically associated to ED-RP. These evidences could help to retarget therapeutic strategies in the management of ED after RP.


Assuntos
Disfunção Erétil/etiologia , Disfunção Erétil/fisiopatologia , Pênis/irrigação sanguínea , Pênis/inervação , Prostatectomia/efeitos adversos , Apoptose , Endotélio/metabolismo , Fibrose , Humanos , Masculino , Pessoa de Meia-Idade , Contração Muscular/fisiologia , Óxido Nítrico/antagonistas & inibidores , Ereção Peniana/fisiologia , Vasodilatação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...